New pages

11:4311:43, 15 April 2025 Vyloy (hist | edit) [900 bytes] Parth Vikram Singh (talk | contribs) (Created page with "{{DrugProjectFormSinglePage |indicationType=treatment |blackBoxWarningTitle='''TITLE''' |blackBoxWarningBody=''Condition Name:'' (Content) |offLabelAdultGuideSupport=There is limited information regarding ''Off-Label Guideline-Supported Use'' of Vyloy in adult patients. |offLabelAdultNoGuideSupport=There is limited information regarding ''Off-Label Non–Guideline-Supported Use'' of Vyloy in adult pa...")

16:4316:43, 13 April 2025 Olipudase alfa (hist | edit) [964 bytes] Parth Vikram Singh (talk | contribs) (Created page with "{{DrugProjectFormSinglePage |authorTag={{PVS}} |indicationType=treatment |blackBoxWarningTitle='''TITLE''' |blackBoxWarningBody=''Condition Name:'' (Content) |offLabelAdultGuideSupport=There is limited information regarding ''Off-Label Guideline-Supported Use'' of Olipudase alfa in adult patients. |offLabelAdultNoGuideSupport=There is limited information regarding ''Off-Label Non–Guideline-Supporte...")
16:4216:42, 13 April 2025 DaxibotulinumtoixnA-lanm (hist | edit) [1,014 bytes] Parth Vikram Singh (talk | contribs) (Created page with "{{DrugProjectFormSinglePage |authorTag={{PVS}} |indicationType=treatment |blackBoxWarningTitle='''TITLE''' |blackBoxWarningBody=''Condition Name:'' (Content) |offLabelAdultGuideSupport=There is limited information regarding ''Off-Label Guideline-Supported Use'' of DaxibotulinumtoixnA-lanm in adult patients. |offLabelAdultNoGuideSupport=There is limited information regarding ''Off-Label Non–Guidelin...")
16:4116:41, 13 April 2025 Eflapegrastim (hist | edit) [23,283 bytes] Parth Vikram Singh (talk | contribs) (Created page with "{{DrugProjectFormSinglePage |authorTag={{PVS}} |indicationType=treatment |blackBoxWarningTitle='''TITLE''' |blackBoxWarningBody=''Condition Name:'' (Content) |offLabelAdultGuideSupport=There is limited information regarding ''Off-Label Guideline-Supported Use'' of Eflapegrastim in adult patients. |offLabelAdultNoGuideSupport=There is limited information regarding ''Off-Label Non–Guideline-Supported...")
16:3816:38, 13 April 2025 Gadopiclenol (hist | edit) [29,538 bytes] Parth Vikram Singh (talk | contribs) (Created page with "{{DrugProjectFormSinglePage |authorTag={{PVS}} |indicationType=treatment |blackBoxWarningTitle='''TITLE''' |blackBoxWarningBody=''Condition Name:'' (Content) |offLabelAdultGuideSupport=There is limited information regarding ''Off-Label Guideline-Supported Use'' of Gadopiclenol in adult patients. |offLabelAdultNoGuideSupport=There is limited information regarding ''Off-Label Non–Guideline-Supported...")
16:3716:37, 13 April 2025 Oomidenepag isopropyl ophthalmic solution (hist | edit) [17,583 bytes] Parth Vikram Singh (talk | contribs) (Created page with "{{DrugProjectFormSinglePage |authorTag={{PVS}} |indicationType=treatment |blackBoxWarningTitle='''TITLE''' |blackBoxWarningBody=''Condition Name:'' (Content) |offLabelAdultGuideSupport=There is limited information regarding ''Off-Label Guideline-Supported Use'' of Oomidenepag isopropyl ophthalmic solution in adult patients. |offLabelAdultNoGuideSupport=There is limited information regarding ''Off-Lab...")
16:3516:35, 13 April 2025 Teclistamab-cqyv (hist | edit) [38,692 bytes] Parth Vikram Singh (talk | contribs) (Created page with "{{DrugProjectFormSinglePage |indicationType=treatment |blackBoxWarningTitle='''TITLE''' |blackBoxWarningBody=''Condition Name:'' (Content) |offLabelAdultGuideSupport=There is limited information regarding ''Off-Label Guideline-Supported Use'' of Teclistamab-cqyv in adult patients. |offLabelAdultNoGuideSupport=There is limited information regarding ''Off-Label Non–Guideline-Supported Use'' of Teclis...")
16:3516:35, 13 April 2025 Mirvetuximab soravtansine-gynx (hist | edit) [42,612 bytes] Parth Vikram Singh (talk | contribs) (Created page with "{{DrugProjectFormSinglePage |authorTag={{PVS}} |indicationType=treatment |blackBoxWarningTitle='''TITLE''' |blackBoxWarningBody=''Condition Name:'' (Content) |offLabelAdultGuideSupport=There is limited information regarding ''Off-Label Guideline-Supported Use'' of Mirvetuximab soravtansine-gynx in adult patients. |offLabelAdultNoGuideSupport=There is limited information regarding ''Off-Label Non–Gu...")
16:3416:34, 13 April 2025 Teplizumab-mzwv (hist | edit) [32,073 bytes] Parth Vikram Singh (talk | contribs) (Created page with "{{DrugProjectFormSinglePage |authorTag={{PVS}} |indicationType=treatment |blackBoxWarningTitle='''TITLE''' |blackBoxWarningBody=''Condition Name:'' (Content) |offLabelAdultGuideSupport=There is limited information regarding ''Off-Label Guideline-Supported Use'' of Teplizumab-mzwv in adult patients. |offLabelAdultNoGuideSupport=There is limited information regarding ''Off-Label Non–Guideline-Support...")
16:3216:32, 13 April 2025 Hyperpolarized Xe-129 (hist | edit) [20,040 bytes] Parth Vikram Singh (talk | contribs) (Created page with "{{DrugProjectFormSinglePage |authorTag={{PVS}} |indicationType=treatment |blackBoxWarningTitle='''TITLE''' |blackBoxWarningBody=''Condition Name:'' (Content) |offLabelAdultGuideSupport=There is limited information regarding ''Off-Label Guideline-Supported Use'' of Hyperpolarized Xe-129 in adult patients. |offLabelAdultNoGuideSupport=There is limited information regarding ''Off-Label Non–Guideline-S...")
16:2616:26, 13 April 2025 Flotufolastat F 18 (hist | edit) [22,497 bytes] Parth Vikram Singh (talk | contribs) (Created page with "{{DrugProjectFormSinglePage |authorTag={{PVS}} |indicationType=treatment |blackBoxWarningTitle='''TITLE''' |blackBoxWarningBody=''Condition Name:'' (Content) |offLabelAdultGuideSupport=There is limited information regarding ''Off-Label Guideline-Supported Use'' of Flotufolastat F 18 in adult patients. |offLabelAdultNoGuideSupport=There is limited information regarding ''Off-Label Non–Guideline-Supp...")
16:2416:24, 13 April 2025 Marstacimab-hncq (hist | edit) [22,860 bytes] Parth Vikram Singh (talk | contribs) (Created page with "{{DrugProjectFormSinglePage |authorTag={{PVS}} |indicationType=treatment |blackBoxWarningTitle='''TITLE''' |blackBoxWarningBody=''Condition Name:'' (Content) |offLabelAdultGuideSupport=There is limited information regarding ''Off-Label Guideline-Supported Use'' of Marstacimab-hncq in adult patients. |offLabelAdultNoGuideSupport=There is limited information regarding ''Off-Label Non–Guideline-Suppor...")
16:2316:23, 13 April 2025 Zolbetuximab-clzb (hist | edit) [32,109 bytes] Parth Vikram Singh (talk | contribs) (Created page with "{{DrugProjectFormSinglePage |authorTag={{PVS}} |indicationType=treatment |blackBoxWarningTitle='''TITLE''' |blackBoxWarningBody=''Condition Name:'' (Content) |offLabelAdultGuideSupport=There is limited information regarding ''Off-Label Guideline-Supported Use'' of Zolbetuximab-clzb in adult patients. |offLabelAdultNoGuideSupport=There is limited information regarding ''Off-Label Non–Guideline-Suppo...")
16:2216:22, 13 April 2025 Orlynvah (hist | edit) [934 bytes] Parth Vikram Singh (talk | contribs) (Created page with "{{DrugProjectFormSinglePage |authorTag={{PVS}} |indicationType=treatment |blackBoxWarningTitle='''TITLE''' |blackBoxWarningBody=''Condition Name:'' (Content) |offLabelAdultGuideSupport=There is limited information regarding ''Off-Label Guideline-Supported Use'' of Orlynvah in adult patients. |offLabelAdultNoGuideSupport=There is limited information regarding ''Off-Label Non–Guideline-Supported Use'...")
16:2216:22, 13 April 2025 Sulopenem etzadroxil, probenecid (hist | edit) [1,054 bytes] Parth Vikram Singh (talk | contribs) (Created page with "{{DrugProjectFormSinglePage |authorTag={{PVS}} |indicationType=treatment |blackBoxWarningTitle='''TITLE''' |blackBoxWarningBody=''Condition Name:'' (Content) |offLabelAdultGuideSupport=There is limited information regarding ''Off-Label Guideline-Supported Use'' of Sulopenem etzadroxil, probenecid in adult patients. |offLabelAdultNoGuideSupport=There is limited information regarding ''Off-Label Non–...")
14:2214:22, 13 April 2025 Ubrogepant (hist | edit) [5,022 bytes] Omid Afkhami-Ardakani (talk | contribs) (Created page with "{{DrugProjectFormSinglePage |authorTag=Omid Afkhami-Ardakani |genericName=Ubrogepant |aOrAn=a |drugClass=Calcitonin Gene-Related Peptide (CGRP) Receptor Antagonist |indicationType=treatment |indication=migraine with or without aura in adults. |adverseReactions=Somnolence, Nausea, Dry mouth, Hypersensitivity reactions including rash, urticaria, and facial edema. |blackBoxWarningTitle='''TITLE''' |blackBoxWarningBody=''<span style="color...")
14:1114:11, 13 April 2025 Enhertu (hist | edit) [6,505 bytes] Omid Afkhami-Ardakani (talk | contribs) (Created page with "{{DrugProjectFormSinglePage |authorTag=Omid Afkhami-Ardakani |genericName=fam-trastuzumab deruxtecan-nxki |aOrAn=an |drugClass=Anti-HER2 antibody |indicationType=treatment |indication=Unresectable or metastatic HER2-positive and HER2-low breast cancer. Also for treating Unresectable or metastatic HER2-mutant non-small cell lung cancer (NSCLC) and Locally advanced or metastatic HER2-positive gastric or gastroesophageal junction (GEJ) adenocarcinoma. |hasBlackBoxWarning=Ye...")
13:3513:35, 13 April 2025 Lemborexant (hist | edit) [5,310 bytes] Omid Afkhami-Ardakani (talk | contribs) (Created page with "{{DrugProjectFormSinglePage |authorTag=Omid Afkhami-Ardakani |genericName=Lemborexant |aOrAn=a |drugClass=Dual Orexin Receptor Antagonist (DORA) |indicationType=treatment |indication=adult patients with insomnia |adverseReactions=Somnolence, Fatigue, Headache, Abnormal dreams, Sleep paralysis, and Hypnagogic hallucinations. |blackBoxWarningTitle='''TITLE''' |blackBoxWarningBody=''Condition...")
13:1713:17, 13 April 2025 Lumateperone tosylate (hist | edit) [4,573 bytes] Omid Afkhami-Ardakani (talk | contribs) (Created page with "{{DrugProjectFormSinglePage |authorTag=Omid Afkhami-Ardakani |genericName=Lumateperone Tosylate |aOrAn=an |drugClass=Atypical Antipsychotic |indicationType=treatment |indication=schizophrenia and depressive episodes associated with bipolar I or II disorder (bipolar depression) in adults. |hasBlackBoxWarning=Yes |adverseReactions=Most common adverse reactions (≥5% and twice the rate of placebo): somnolence/sedation, dry mouth. |blackBoxWarningTitle=Increased Mortalit...")
13:0213:02, 13 April 2025 Brilliant Blue G Ophthalmic Solution (hist | edit) [4,137 bytes] Omid Afkhami-Ardakani (talk | contribs) (Created page with "{{DrugProjectFormSinglePage |authorTag=Omid Afkhami-Ardakani |genericName=Brilliant Blue G |aOrAn=a |drugClass=Disclosing Agent |indicationType=procedure |indication=staining the internal limiting membrane (ILM) during ophthalmic surgery. |blackBoxWarningTitle='''TITLE''' |blackBoxWarningBody=''Condition Name:'' (Content) |fdaLIADAdult=Inject TissueBlue 0.025% directly into a Balanced Salt Solutio...")
12:5112:51, 13 April 2025 Padcev (hist | edit) [6,010 bytes] Omid Afkhami-Ardakani (talk | contribs) (Created page with "{{DrugProjectFormSinglePage |authorTag=Omid Afkhami-Ardakani |genericName=Enfortumab vedotin-ejfv |aOrAn=an |drugClass=Antineoplastic Agent |indicationType=treatment |indication=Locally advanced or metastatic urothelial cancer (mUC) in adult patients and Locally advanced or metastatic urothelial cancer (mUC) in adult patients who are ineligible for cisplatin-containing chemotherapy. |hasBlackBoxWarning=Yes |adverseReactions=Rash, alopecia, dry skin, pruritus, perip...")
12:2912:29, 13 April 2025 Golodirsen (hist | edit) [4,122 bytes] Omid Afkhami-Ardakani (talk | contribs) (Created page with "{{DrugProjectFormSinglePage |authorTag=Omid Afkhami-Ardakani |genericName=Golodirsen |aOrAn=an |drugClass=Antisense oligonucleotide |indicationType=treatment |indication=Duchenne muscular dystrophy (DMD) in patients who have a confirmed mutation of the DMD gene that is amenable to exon 53 skipping. |adverseReactions=Common Adverse Reactions (≥20% incidence): Headache, fever, fall, abdominal pain, nasopharyngitis, cough, vomiting, and nausea. |blackBoxWarningTitle=''...")
12:1212:12, 13 April 2025 Voxelotor (hist | edit) [5,316 bytes] Omid Afkhami-Ardakani (talk | contribs) (Created page with "{{DrugProjectFormSinglePage |authorTag=Omid Afkhami-Ardakani |genericName=Voxelotor |aOrAn=a |drugClass=Hemoglobin S polymerization inhibitor |indicationType=treatment |indication=sickle cell disease (SCD) in adults and pediatric patients aged 4 years and older. |adverseReactions=Common Adverse Reactions (≥10% incidence): Headache, diarrhea, abdominal pain, nausea, rash, and pyrexia. Note: As of September 2024, Pfizer has voluntarily withdrawn Oxbryta from al...")
11:5111:51, 13 April 2025 Cenobamate (hist | edit) [7,196 bytes] Omid Afkhami-Ardakani (talk | contribs) (Created page with "{{DrugProjectFormSinglePage |authorTag=Omid Afkhami-Ardakani |genericName=cenobamate |aOrAn=a |drugClass=Sodium Channel Inhibitor |indicationType=treatment |indication=partial-onset seizures in adult patients. |adverseReactions=dizziness, somnolence, fatigue, headache, nausea, constipation, balance disorder, and rash. |blackBoxWarningTitle='''TITLE''' |blackBoxWarningBody=''Condition Name:'' (Content...")

14:3514:35, 12 April 2025 Flurpiridaz F 18 (hist | edit) [23,419 bytes] Parth Vikram Singh (talk | contribs) (Created page with "{{DrugProjectFormSinglePage |indicationType=treatment |blackBoxWarningTitle='''TITLE''' |blackBoxWarningBody=''Condition Name:'' (Content) |offLabelAdultGuideSupport=There is limited information regarding ''Off-Label Guideline-Supported Use'' of Flurpiridaz F 18 in adult patients. |offLabelAdultNoGuideSupport=There is limited information regarding ''Off-Label Non–Guideline-Supported Use'' of Flurpi...")
13:4513:45, 12 April 2025 Xanomeline and trospium chloride (hist | edit) [46,444 bytes] Parth Vikram Singh (talk | contribs) (Created page with "{{DrugProjectFormSinglePage |authorTag={{PVS}} |indicationType=treatment |blackBoxWarningTitle='''TITLE''' |blackBoxWarningBody=''Condition Name:'' (Content) |offLabelAdultGuideSupport=There is limited information regarding ''Off-Label Guideline-Supported Use'' of Xanomeline and trospium chloride in adult patients. |offLabelAdultNoGuideSupport=There is limited information regarding ''Off-Label Non–...")
13:4413:44, 12 April 2025 Lebrikizumab-lbkz (hist | edit) [39,416 bytes] Parth Vikram Singh (talk | contribs) (Created page with "{{DrugProjectFormSinglePage |authorTag={{PVS}} |indicationType=treatment |blackBoxWarningTitle='''TITLE''' |blackBoxWarningBody=''Condition Name:'' (Content) |offLabelAdultGuideSupport=There is limited information regarding ''Off-Label Guideline-Supported Use'' of Lebrikizumab-lbkz in adult patients. |offLabelAdultNoGuideSupport=There is limited information regarding ''Off-Label Non–Guideline-Suppo...")
13:4413:44, 12 April 2025 Axatilimab-csfr (hist | edit) [23,789 bytes] Parth Vikram Singh (talk | contribs) (Created page with "{{DrugProjectFormSinglePage |authorTag={{PVS}} |indicationType=treatment |blackBoxWarningTitle='''TITLE''' |blackBoxWarningBody=''Condition Name:'' (Content) |offLabelAdultGuideSupport=There is limited information regarding ''Off-Label Guideline-Supported Use'' of Axatilimab-csfr in adult patients. |offLabelAdultNoGuideSupport=There is limited information regarding ''Off-Label Non–Guideline-Support...")
13:4313:43, 12 April 2025 Nemolizumab-ilto (hist | edit) [24,525 bytes] Parth Vikram Singh (talk | contribs) (Created page with "{{DrugProjectFormSinglePage |authorTag={{PVS}} |indicationType=treatment |blackBoxWarningTitle='''TITLE''' |blackBoxWarningBody=''Condition Name:'' (Content) |offLabelAdultGuideSupport=There is limited information regarding ''Off-Label Guideline-Supported Use'' of Nemolizumab-ilto in adult patients. |offLabelAdultNoGuideSupport=There is limited information regarding ''Off-Label Non–Guideline-Suppor...")
13:4213:42, 12 April 2025 Crovalimab-akkz (hist | edit) [50,869 bytes] Parth Vikram Singh (talk | contribs) (Created page with "{{DrugProjectFormSinglePage |authorTag={{PVS}} |indicationType=treatment |blackBoxWarningTitle='''TITLE''' |blackBoxWarningBody=''Condition Name:'' (Content) |offLabelAdultGuideSupport=There is limited information regarding ''Off-Label Guideline-Supported Use'' of Crovalimab-akkz in adult patients. |offLabelAdultNoGuideSupport=There is limited information regarding ''Off-Label Non–Guideline-Support...")

16:3716:37, 11 April 2025 Nirmatrelvir and ritonavir (hist | edit) [66,238 bytes] Parth Vikram Singh (talk | contribs) (Created page with "{{DrugProjectFormSinglePage |authorTag={{PVS}} |genericName=nirmatrelvir and ritonavir |aOrAn=a |drugClass=strong CYP3A inhibitor, |indicationType=treatment |indication=nirmatrelvir, a severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) main protease (Mpro: also referred to as 3CLpro or nsp5 protease) inhibitor, and ritonavir, an HIV-1 protease inhibitor and CYP3A inhibitor,that is FDA approved for the treatment of mild-to-moderate coronavirus disease 2019 (COVI...")
11:3311:33, 11 April 2025 Nirmatrelvir, ritonavir (hist | edit) [66,382 bytes] Parth Vikram Singh (talk | contribs) (Created page with "{{DrugProjectFormSinglePage |authorTag={{PVS}} |genericName=nirmatrelvir and ritonavir |aOrAn=a |drugClass=strong CYP3A inhibitor, |indicationType=treatment |indication=PAXLOVID is a nirmatrelvir, a severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) main protease (Mpro: also referred to as 3CLpro or nsp5 protease) inhibitor, and ritonavir, an HIV-1 protease inhibitor and CYP3A inhibitor,that is FDA approved for the treatment of mild-to-moderate coronavirus dise...")
01:4301:43, 11 April 2025 Drug coated balloon (hist | edit) [75,458 bytes] Parth Vikram Singh (talk | contribs) (Created page with "__NOTOC__ thumb|right|250px|An example of a drug-eluting stent. This is the TAXUS™ Express2™ Paclitaxel-Eluting Coronary Stent System, which releases [[paclitaxel.]] {{SI}} {{CMG}} ==Overview== In cardiology, a '''drug-eluting stent''' is a stent (a scaffold) placed into narrowed, diseased coronary arteries that slowly releases a drug to block cell proliferation. This prevents s...")

19:4919:49, 10 April 2025 Zanidatamab-hrii (hist | edit) [24,381 bytes] Parth Vikram Singh (talk | contribs) (Created page with "{{DrugProjectFormSinglePage |authorTag={{PVS}} |genericName=zanidatamab-hrii |aOrAn=a |drugClass=bispecific HER2-directed antibody |indicationType=treatment |indication=ZIIHERA is a bispecific HER2-directed antibody that is FDA approved for the treatment of adults with previously treated, unresectable or metastatic HER2-positive (IHC 3+) biliary tract cancer (BTC), as detected by an FDA-approved test. |adverseReactions=*...")
11:5311:53, 10 April 2025 Givinostat Hydrochloride (hist | edit) [14,877 bytes] Alara E. Dagsali (talk | contribs) (Created page with "{{DrugProjectFormSinglePage |authorTag= Alara Ece Dagsali, M.D. |genericName=givinostat |aOrAn=an |drugClass=inhibits class I and class II histone deacetylases (HDACs) and several pro-inflammatory cytokines |indicationType=treatment |indication=of Duchenne muscular dystrophy (DMD) in patients 6 years of age and older. |adverseReactions=*Hematological Changes *Increased Triglycerides *Gastrointestinal Disturbances *QTc Prolongation |blackBoxWarningTitle='...")
10:3310:33, 10 April 2025 Sotatercept-csrk (hist | edit) [18,496 bytes] Alara E. Dagsali (talk | contribs) (Created page with "{{DrugProjectFormSinglePage |authorTag= Alara Ece Dagsali, M.D. |genericName= Alara Ece Dagsali, M.D. |aOrAn=an |drugClass=activin signalling inhibitor |indicationType=treatment |indication=of adults with pulmonary arterial hypertension (PAH, World Health Organization [WHO] Group 1) to increase exercise capacity, improve WHO functional class (FC), and reduce the risk of clinical worsening events. |adverseReactions=*Erythrocytosis *Severe Thr...")
10:1410:14, 10 April 2025 Givinostat (hist | edit) [2,643 bytes] Parth Vikram Singh (talk | contribs) (Created page with "{{DrugProjectFormSinglePage |authorTag={{PVS}} |indicationType=treatment |blackBoxWarningTitle='''TITLE''' |blackBoxWarningBody=''Condition Name:'' (Content) |offLabelAdultGuideSupport=There is limited information regarding ''Off-Label Guideline-Supported Use'' of Givinostat in adult patients. |offLabelAdultNoGuideSupport=There is limited information regarding ''Off-Label Non–Guideline-Supported Us...")
09:5609:56, 10 April 2025 Duvyzat (hist | edit) [4,812 bytes] Parth Vikram Singh (talk | contribs) (Created page with "{{DrugProjectFormSinglePage |authorTag={{PVS}} |genericName=givinostat |aOrAn=a |indicationType=treatment |blackBoxWarningTitle='''TITLE''' |blackBoxWarningBody=''Condition Name:'' (Content) |offLabelAdultGuideSupport=There is limited information regarding ''Off-Label Guideline-Supported Use'' of Duvyzat in adult patients. |offLabelAdultNoGuideSupport=There is limited information regarding ''Off-Labe...")
06:0306:03, 10 April 2025 Nogapendekin alfa inbakicept-pmln (hist | edit) [16,208 bytes] Alara E. Dagsali (talk | contribs) (Created page with "{{DrugProjectFormSinglePage |authorTag= Alara Ece Dagsali, M.D. |genericName=nogapendekin alfa inbakicept-pmln |aOrAn=an |drugClass=interleukin-15 (IL-15) receptor agonist |indicationType=treatment |indication=of adult patients with BCG-unresponsive nonmuscle invasive bladder cancer (NMIBC) with carcinoma in situ (CIS) with or without papillary tumors. |adverseReactions=The most common (≥15%) adverse reactions, were increased creatinine, dysuria, hematuri...")

15:1515:15, 8 April 2025 Givosiran (hist | edit) [7,932 bytes] Omid Afkhami-Ardakani (talk | contribs) (Created page with "{{DrugProjectFormSinglePage |authorTag=Omid Afkhami-Ardakani |genericName=Givosiran |aOrAn=a |drugClass=Small interfering RNA (siRNA) agent |indicationType=treatment |indication=acute hepatic porphyria (AHP) in adults. |adverseReactions=nausea, injection site reactions, fatigue, and elevated liver enzymes. |blackBoxWarningTitle='''TITLE''' |blackBoxWarningBody=''Condition Name:'' (Content) |fdaLIADAd...")
09:5609:56, 8 April 2025 Levacetylleucine (hist | edit) [22,144 bytes] Parth Vikram Singh (talk | contribs) (Created page with "{{DrugProjectFormSinglePage |authorTag={{PVS}} |genericName=levacetylleucine |indicationType=treatment |indication=AQNEURSA is FDA approved for the treatment of neurological manifestations of Niemann-Pick disease type C (NPC) in adults and pediatric patients weighing ≥15 kg. |hasBlackBoxWarning=Yes |adverseReactions=Most common adverse reactions (incidence ≥5% and greater than placebo) are abdominal pain, dysphagia, upper respiratory tract infections, and vomiting. |...")

15:2015:20, 7 April 2025 Mavorixafor (hist | edit) [31,950 bytes] Parth Vikram Singh (talk | contribs) (Created page with "{{DrugProjectFormSinglePage |authorTag={{PVS}} |indicationType=treatment |blackBoxWarningTitle='''TITLE''' |blackBoxWarningBody=''Condition Name:'' (Content) |offLabelAdultGuideSupport=There is limited information regarding ''Off-Label Guideline-Supported Use'' of Mavorixafor in adult patients. |offLabelAdultNoGuideSupport=There is limited information regarding ''Off-Label Non–Guideline-Supported U...")
14:2914:29, 7 April 2025 Adakveo (hist | edit) [5,828 bytes] Omid Afkhami-Ardakani (talk | contribs) (Created page with "{{DrugProjectFormSinglePage |genericName=Crizanlizumab-tmca |aOrAn=a |drugClass=Monoclonal Antibody |indicationType=prophylaxis |indication=vaso-occlusive crises (VOCs) in adults and pediatric patients aged 16 years and older with sickle cell disease. |adverseReactions=Nausea, Arthralgia (joint pain), Back pain, and Pyrexia (fever). |blackBoxWarningTitle='''TITLE''' |blackBoxWarningBody=''Condition...")
10:1010:10, 7 April 2025 Imetelstat (hist | edit) [36,430 bytes] Parth Vikram Singh (talk | contribs) (Created page with "{{DrugProjectFormSinglePage |authorTag={{PVS}} |indicationType=treatment |blackBoxWarningTitle='''TITLE''' |blackBoxWarningBody=''Condition Name:'' (Content) |offLabelAdultGuideSupport=There is limited information regarding ''Off-Label Guideline-Supported Use'' of Imetelstat in adult patients. |offLabelAdultNoGuideSupport=There is limited information regarding ''Off-Label Non–Guideline-Supported Us...")
03:4003:40, 7 April 2025 Berdazimer (hist | edit) [15,716 bytes] Parth Vikram Singh (talk | contribs) (Created page with "{{DrugProjectFormSinglePage |indicationType=treatment |indication=abc |blackBoxWarningTitle='''TITLE''' |blackBoxWarningBody=''Condition Name:'' (Content) |offLabelAdultGuideSupport=There is limited information regarding ''Off-Label Guideline-Supported Use'' of Berdazimer in adult patients. |offLabelAdultNoGuideSupport=There is limited information regarding ''Off-Label Non–Guideline-Supported Use''...")

10:3310:33, 6 April 2025 Elafibranor (hist | edit) [45,146 bytes] Parth Vikram Singh (talk | contribs) (Created page with "{{DrugProjectFormSinglePage |authorTag=Parth Vikram Singh |indicationType=treatment |blackBoxWarningTitle='''TITLE''' |blackBoxWarningBody=''Condition Name:'' (Content) |offLabelAdultGuideSupport=There is limited information regarding ''Off-Label Guideline-Supported Use'' of Elafibranor in adult patients. |offLabelAdultNoGuideSupport=There is limited information regarding ''Off-Label Non–Guideline-...")
09:1809:18, 6 April 2025 SOFDRA (hist | edit) [24,783 bytes] Parth Vikram Singh (talk | contribs) (Created page with "{{DrugProjectFormSinglePage |authorTag=Parth Vikram Singh |genericName=sofpironium |aOrAn=an |indicationType=treatment |indication=SOFDRA is an anticholinergic FDA approved for the treatment of primary axillary hyperhidrosis in adults and pediatric patients 9 years of age and older. |adverseReactions=• Most common adverse reactions (incidence ≥2%) are:  dry mouth,  vision blurred,  application site pain,  application site erythema,  mydriasis...")
07:1507:15, 6 April 2025 Sofpironium (hist | edit) [21,666 bytes] Parth Vikram Singh (talk | contribs) (Created page with "{{DrugProjectFormSinglePage |authorTag=Parth Vikram Singh |genericName=sofpironium |aOrAn=an |indicationType=treatment |indication=SOFDRA is an anticholinergic approved for the treatment of primary axillary hyperhidrosis in adults and pediatric patients 9 years of age and older. |blackBoxWarningTitle='''TITLE''' |blackBoxWarningBody=''Condition Name:'' (Content) |offLabelAdultGuideSupport=There is li...")

10:2310:23, 5 April 2025 Ensifentrine (hist | edit) [29,428 bytes] Parth Vikram Singh (talk | contribs) (Created page with "{{DrugProjectFormSinglePage |authorTag=Parth Vikram Singh |genericName=ensifentrine |aOrAn=a |indicationType=treatment |indication=OHTUVAYRE is a phosphodiesterase 3 (PDE3) inhibitor and phosphodiesterase 4 (PDE4) inhibitor approved for the maintenance treatment of chronic obstructive pulmonary disease (COPD) in adult patients. |blackBoxWarningTitle='''TITLE''' |blackBoxWarningBody=''Condition Name:'...")

17:1317:13, 3 April 2025 Vorasidenib (hist | edit) [40,798 bytes] Parth Vikram Singh (talk | contribs) (Created page with "{{DrugProjectFormSinglePage |authorTag=Parth Vikram Singh |indicationType=treatment |blackBoxWarningTitle='''TITLE''' |blackBoxWarningBody=''Condition Name:'' (Content) |offLabelAdultGuideSupport=There is limited information regarding ''Off-Label Guideline-Supported Use'' of Vorasidenib in adult patients. |offLabelAdultNoGuideSupport=There is limited information regarding ''Off-Label Non–Guideline-...")

New pages

15 April 2025

13 April 2025

12 April 2025

11 April 2025

10 April 2025

8 April 2025

7 April 2025

6 April 2025

5 April 2025

3 April 2025

Navigation menu

Search